File:Oocyte BMP15 and GDF9 effects.jpg - Revision history

Z8600021: /* Oocyte BMP15 and GDF9 Effects */

2018-08-07T00:23:23Z

Oocyte BMP15 and GDF9 Effects

← Older revision		Revision as of 11:23, 7 August 2018
Line 3:		Line 3:


	:Links: {{Oocyte}} \| [[Developmental_Signals_-_Bone_Morphogenetic_Protein\|BMP]] \| {{~~bovine~~}}		:Links: {{Oocyte}} \| [[Developmental_Signals_-_Bone_Morphogenetic_Protein\|BMP]] \| {{cow}}
	===Reference===		===Reference===
	{{#pmid:25058588\|PMID25058588}}		{{#pmid:25058588\|PMID25058588}}

Z8600021 at 00:23, 7 August 2018

2018-08-07T00:23:04Z

← Older revision		Revision as of 11:23, 7 August 2018
Line 3:		Line 3:


	:Links: [[Oocyte ~~Development]]~~ \| [[Developmental_Signals_-_Bone_Morphogenetic_Protein\|BMP]] \| ~~[[Bovine Development]]~~		:Links: {{Oocyte}} \| [[Developmental_Signals_-_Bone_Morphogenetic_Protein\|BMP]] \| {{bovine}}
	===Reference===		===Reference===
			{{#pmid:25058588\|PMID25058588}}
	~~<pubmed>~~25058588~~</pubmed>\| [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110049 PMC4110049]~~ \| ~~[http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0103563 PLoS One]~~

	====Copyright====		====Copyright====

Z8600021 at 03:25, 10 August 2014

2014-08-10T03:25:45Z

← Older revision		Revision as of 14:25, 10 August 2014
Line 3:		Line 3:


			:Links: [[Oocyte Development]] \| [[Developmental_Signals_-_Bone_Morphogenetic_Protein\|BMP]] \| [[Bovine Development]]
	===Reference===		===Reference===

Z8600021 at 03:04, 10 August 2014

2014-08-10T03:04:13Z

← Older revision		Revision as of 14:04, 10 August 2014
Line 8:		Line 8:

	====Copyright====		====Copyright====
	© 2014 Sudiman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.		© 2014 Sudiman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Z8600021 at 03:02, 10 August 2014

2014-08-10T03:02:35Z

← Older revision		Revision as of 14:02, 10 August 2014
Line 1:		Line 1:
	==Oocyte BMP15 and GDF9 Effects==		==Oocyte BMP15 and GDF9 Effects==
	Representative micrographs of intra-oocyte NAD(P)H (A, C) and FAD (B, D) autofluorescence and GSH fluorescence (E, F), after treatment with different forms of BMP15 (mature BMP15 and pro-mature BMP15) or mature GDF9 at 100 ng/ml, in the absence (A, B, E) or presence (C, D, F) of FSH.		Representative micrographs of bovine intra-oocyte NAD(P)H (A, C) and FAD (B, D) autofluorescence and GSH fluorescence (E, F), after treatment with different forms of BMP15 (mature BMP15 and pro-mature BMP15) or mature GDF9 at 100 ng/ml, in the absence (A, B, E) or presence (C, D, F) of FSH.


	~~Pone.0103563.g005.jpg~~		===Reference===

	~~===Bone morphogenetic protein 15 in the pro-mature complex form enhances bovine oocyte developmental competence===~~		<pubmed>25058588</pubmed>\| [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4110049 PMC4110049] \| [http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0103563 PLoS One]

	~~PLoS One.~~ 2014 ~~Jul 24;9(7):e103563. doi: 10.1371/journal.pone~~.~~0103563. eCollection 2014~~.		====Copyright====
			© 2014 Sudiman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

	~~Sudiman J1, Sutton-McDowall ML1, Ritter LJ1, White MA1, Mottershead DG1, Thompson JG1, Gilchrist RB2.~~

	~~Abstract~~

	Developmental competence of in vitro matured (IVM) oocytes needs to be improved and this can potentially be achieved by adding recombinant bone morphogenetic protein 15 (BMP15) or growth differentiation factor (GDF9) to IVM. The aim of this study was to determine the effect of a purified pro-mature complex form of recombinant human BMP15 versus the commercially available bioactive forms of BMP15 and GDF9 (both isolated mature regions) during IVM on bovine embryo development and metabolic activity. Bovine cumulus oocyte complexes (COCs) were matured in vitro in control medium or treated with 100 ng/ml pro-mature BMP15, mature BMP15 or mature GDF9 +/- FSH. Metabolic measures of glucose uptake and lactate production from COCs and autofluorescence of NAD(P)H, FAD and GSH were measured in oocytes after IVM. Following in vitro fertilisation and embryo culture, day 8 blastocysts were stained for cell numbers. COCs matured in medium +/- FSH containing pro-mature BMP15 displayed significantly improved blastocyst development (57.7±3.9%, 43.5±4.2%) compared to controls (43.3±2.4%, 28.9±3.7%) and to mature GDF9+FSH (36.1±3.0%). The mature form of BMP15 produced intermediate levels of blastocyst development; not significantly different to control or pro-mature BMP15 levels. Pro-mature BMP15 increased intra-oocyte NAD(P)H, and reduced glutathione (GSH) levels were increased by both forms of BMP15 in the absence of FSH. Exogenous BMP15 in its pro-mature form during IVM provides a functional source of oocyte-secreted factors to improve bovine blastocyst development. This form of BMP15 may prove useful for improving cattle and human artificial reproductive technologies.

			Pone.0103563.g005.jpg

	~~PMID 25058588~~		[[Category:Bovine]][[Category:Oocyte]]

Z8600021: ==Oocyte BMP15 and GDF9 Effects== Representative micrographs of intra-oocyte NAD(P)H (A, C) and FAD (B, D) autofluorescence and GSH fluorescence (E, F), after treatment with different forms of BMP15 (mature BMP15 and pro-mature BMP15) or mature GDF9 at...

2014-08-10T02:59:02Z

New page

==Oocyte BMP15 and GDF9 Effects==
Representative micrographs of intra-oocyte NAD(P)H (A, C) and FAD (B, D) autofluorescence and GSH fluorescence (E, F), after treatment with different forms of BMP15 (mature BMP15 and pro-mature BMP15) or mature GDF9 at 100 ng/ml, in the absence (A, B, E) or presence (C, D, F) of FSH.

Pone.0103563.g005.jpg

===Bone morphogenetic protein 15 in the pro-mature complex form enhances bovine oocyte developmental competence===

PLoS One. 2014 Jul 24;9(7):e103563. doi: 10.1371/journal.pone.0103563. eCollection 2014.

Sudiman J1, Sutton-McDowall ML1, Ritter LJ1, White MA1, Mottershead DG1, Thompson JG1, Gilchrist RB2.

Abstract

Developmental competence of in vitro matured (IVM) oocytes needs to be improved and this can potentially be achieved by adding recombinant bone morphogenetic protein 15 (BMP15) or growth differentiation factor (GDF9) to IVM. The aim of this study was to determine the effect of a purified pro-mature complex form of recombinant human BMP15 versus the commercially available bioactive forms of BMP15 and GDF9 (both isolated mature regions) during IVM on bovine embryo development and metabolic activity. Bovine cumulus oocyte complexes (COCs) were matured in vitro in control medium or treated with 100 ng/ml pro-mature BMP15, mature BMP15 or mature GDF9 +/- FSH. Metabolic measures of glucose uptake and lactate production from COCs and autofluorescence of NAD(P)H, FAD and GSH were measured in oocytes after IVM. Following in vitro fertilisation and embryo culture, day 8 blastocysts were stained for cell numbers. COCs matured in medium +/- FSH containing pro-mature BMP15 displayed significantly improved blastocyst development (57.7±3.9%, 43.5±4.2%) compared to controls (43.3±2.4%, 28.9±3.7%) and to mature GDF9+FSH (36.1±3.0%). The mature form of BMP15 produced intermediate levels of blastocyst development; not significantly different to control or pro-mature BMP15 levels. Pro-mature BMP15 increased intra-oocyte NAD(P)H, and reduced glutathione (GSH) levels were increased by both forms of BMP15 in the absence of FSH. Exogenous BMP15 in its pro-mature form during IVM provides a functional source of oocyte-secreted factors to improve bovine blastocyst development. This form of BMP15 may prove useful for improving cattle and human artificial reproductive technologies.

PMID 25058588